Search results
Results from the WOW.Com Content Network
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. [3] [4] As one of the world's largest independent biotechnology companies, Amgen has approximately 24,000 staff in total as of 2022.
But with the pharma industry in the crosshairs for pricing, Amgen is keeping a focus on increased volumes of its products. "In 2018, this industry turned from price increases for 35 years or so to ...
Company Sales (USD millions/year) ∆ vs 2014 1 Adalimumab: Humira Biologic Rheumatoid arthritis: AbbVie Inc. 14,012 1,469 2 Ledipasvir/sofosbuvir: Harvoni Small molecule Hepatitis C: Gilead Sciences: 13,864 11,737 3 Etanercept: Enbrel Biologic Rheumatoid arthritis: Amgen. Pfizer. 8,697 4,009 4 Infliximab: Remicade Biologic Crohn's Disease ...
Before you buy stock in Amgen, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amgen wasn’t one ...
Amgen shares trade at just 13.4 times forward earnings, a remarkable discount to the S&P 500's multiple of nearly 24. This valuation gap seems overdone, given Amgen's cash-generating power.
In October 2014, the company acquired the US sales and marketing rights to the osteoarthritis drug Pennsaid from Nuvo Research for $45 million. [8] In March 2015, the company acquired Hyperion Therapeutics for $1.1 billion, increasing Horizon's orphan disease drug portfolio. [9] In December, the company acquired Crealta Holdings for $510 ...
Icos Corporation (trademark ICOS) was an American biotechnology company and the largest biotechnology company in the U.S. state of Washington, before it was sold to Eli Lilly and Company in 2007. It was founded in 1989 by David Blech , Isaac Blech , Robert Nowinski , and George Rathmann , a pioneer in the industry and chief executive officer ...
Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months. Despite a string of solid earnings reports from the biotechnology giant ...